Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Boston Scientific Corp (BSX)
Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Boston Scientific Corp 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 USA

P: 508-683-4000 F: 508-650-8923

Description:

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Key Statistics

Overview:

Market Capitalization, $K 70,060,312
Enterprise Value, $K 78,067,312
Shares Outstanding, K 1,434,780
Annual Sales, $ 12,682 M
Annual Net Income, $ 698,000 K
Last Quarter Sales, $ 3,242 M
Last Quarter Net Income, $ 140,000 K
60-Month Beta 0.79
% of Insider Shareholders 0.66%
% of Institutional Shareholders 90.23%
Float, K 1,425,311
% Float 99.34%
Short Volume Ratio 0.48

Growth:

1-Year Return 9.62%
3-Year Return 59.52%
5-Year Return 78.73%
5-Year Revenue Growth 40.16%
5-Year Earnings Growth 35.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.45 on 02/01/23
Next Earnings Date 04/26/23
Earnings Per Share ttm 1.71
EPS Growth vs. Prev Qtr 4.65%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 11/06/03

BSX Ratios

Ratio
Price/Earnings ttm 28.04
Price/Earnings forward 25.25
Price/Earnings to Growth 2.26
Return-on-Equity % 14.29%
Return-on-Assets % 7.67%
Profit Margin % 5.50
Net Margin % 7.57
Debt/Equity 0.49
Price/Sales 5.42
Price/Cash Flow 18.43
Price/Book 3.91
Book Value/Share 12.27
Interest Coverage 3.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar